Clin2
NCT04099966Possibly a fitRecruiting

Stem cell transplant to treat high-risk blood cancers

Acute LeukemiaSevere Aplastic AnemiaNon-hodgkin LymphomaHodgkin LymphomaKostmannDiamond Blackfan AnemiaAmegakaryocytic ThrombocytopeniaSickle Cell Disease

Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy clinical trials.

This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
1 day to 30 years
Study type
Interventional

Who can take part

  • You have a high-risk blood or bone marrow condition such as certain leukemia, MDS, lymphoma, or specific non-cancer blood disorders
  • You are between 0 and 30 years old
  • You can use the trial’s treatment plan because your heart, liver, and kidney tests are good enough (organ function)
  • You do not have a serious uncontrolled infection when you start
  • Your activity level (Karnofsky/Lansky score) is 60 or higher
  • If you recently had a donor stem cell transplant, it must be more than 6 months ago (unless this is a boost)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04195633Recruiting· Phase 2
Haploidentical donor stem cell transplant to treat blood cancers

This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.

Seattle, Washington
NCT03314974Recruiting· Phase 2
Stem cell transplant study for blood cancers

This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.

Minneapolis, Minnesota
NCT07493538Recruiting· Phase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers

This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.

Minneapolis, Minnesota
NCT05031897Recruiting· Phase 2
Haplo transplant with reduced donor mismatch and radiation

This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.

Philadephia, Pennsylvania
NCT03653338Recruiting· Phase 1/Phase 2
Bone marrow transplant using donor blood to treat sickle cell

This trial tests a specific type of bone marrow transplant for people with sickle cell disease (or certain other blood disorders) who have had serious complications despite standard care. It aims to see if removing the patient’s immune cells and using a matched donor’s cells can improve outcomes and reduce complications.

Pittsburgh, Pennsylvania
NCT06872333Recruiting· Phase 2
Stem cell transplant from a matched sibling for blood disorders

This trial tests whether a stem cell transplant from a fully matched sibling donor can help people with serious blood disorders like sickle cell disease or thalassemia. It aims to replace the faulty blood system with a healthy one from the donor.

Minneapolis, Minnesota

Hear when a new Acute Leukemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.